Morgan Stanley
GLMD icon

Morgan Stanley’s Galmed Pharmaceuticals GLMD Stock Holding History

Morgan Stanley’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31 Sell
7
-13
-65% -$65 ﹤0.01% 8228
2026
Q1 		$77 Sell
20
-17
-46% -$92 ﹤0.01% 7852
2025
Q4 		$224 Buy
37
+25
+208% +$234 ﹤0.01% 7613
2025
Q3 		$135 Sell
12
-4,185
-100% -$53.8K ﹤0.01% 7637
2025
Q2 		$61.8K Buy
4,197
+3,274
+355% +$38.5K ﹤0.01% 6290
2025
Q1 		$10.6K Sell
923
-643
-41% -$12.6K ﹤0.01% 6781
2024
Q4 		$40K Buy
1,566
+1,553
+11,946% +$42.1K ﹤0.01% 6359
2024
Q3 		$713 Sell
13
-364
-97% -$12.7K ﹤0.01% 7270
2024
Q2 		$9.96K Buy
377
+226
+150% +$7.93K ﹤0.01% 6685
2024
Q1 		$5.02K Sell
151
-708
-82% -$25.5K ﹤0.01% 6887
2023
Q4 		$37.5K Buy
859
+650
+311% +$24.8K ﹤0.01% 6250
2023
Q3 		$12.4K Buy
209
+79
+61% +$8.38K ﹤0.01% 6654
2023
Q2 		$37.4K Sell
130
-12
-8% -$5.19K ﹤0.01% 6326
2023
Q1 		$87.1K Buy
142
+16
+13% +$13.7K ﹤0.01% 6069
2022
Q4 		$90.4K Sell
126
-6
-5% -$3.14K ﹤0.01% 6023
2022
Q3 		$59K Sell
132
-4
-3% -$2.73K ﹤0.01% 6333
2022
Q2 		$127K Buy
136
+21
+18% +$27.8K ﹤0.01% 6145
2022
Q1 		$263K Buy
115
+3
+3% +$6.8K ﹤0.01% 5777
2021
Q4 		$293K Sell
112
-2
-2% -$7.22K ﹤0.01% 5859
2021
Q3 		$459K Sell
114
-14
-11% -$58.7K ﹤0.01% 5551
2021
Q2 		$560K Sell
128
-1
-0.8% -$4.35K ﹤0.01% 5459
2021
Q1 		$636K Buy
129
+16
+14% +$88.5K ﹤0.01% 5021
2020
Q4 		$505K Buy
113
+23
+26% +$115K ﹤0.01% 5075
2020
Q3 		$459K Buy
90
+13
+17% +$84.9K ﹤0.01% 4692
2020
Q2 		$530K Buy
77
+23
+43% +$155K ﹤0.01% 4567
2020
Q1 		$269K Buy
54
+11
+26% +$83.6K ﹤0.01% 4739
2019
Q4 		$360K Buy
43
+32
+291% +$220K ﹤0.01% 5111
2019
Q3 		$78K Buy
11
+1
+10% +$8.03K ﹤0.01% 5531
2019
Q2 		$109K Buy
10
+6
+150% +$61.9K ﹤0.01% 5283
2019
Q1 		$52K Sell
4
-8
-67% -$93.1K ﹤0.01% 5649
2018
Q4 		$117K Sell
12
-79
-87% -$1.1M ﹤0.01% 5494
2018
Q3 		$1.78M Sell
91
-66
-42% -$1.24M ﹤0.01% 4089
2018
Q2 		$2.69M Buy
157
+16
+11% +$185K ﹤0.01% 3803
2018
Q1 		$1.13M Buy
141
+25
+22% +$291K ﹤0.01% 4457
2017
Q4 		$1.53M Buy
116
+32
+38% +$378K ﹤0.01% 4254
2017
Q3 		$1.11M Buy
84
+17
+25% +$188K ﹤0.01% 4351
2017
Q2 		$596K Buy
67
+28
+72% +$211K ﹤0.01% 4688
2017
Q1 		$274K Buy
39
+10
+34% +$63.8K ﹤0.01% 5164
2016
Q4 		$147K Buy
29
+22
+314% +$116K ﹤0.01% 5451
2016
Q3 		$43K Buy
7
+4
+133% +$24.1K ﹤0.01% 5648
2016
Q2 		$22K Hold
3
– – ﹤0.01% 5816
2016
Q1 		$24K Sell
3
-1
-25% -$7.84K ﹤0.01% 5865
2015
Q4 		$48K Sell
4
-1
-20% -$12.8K ﹤0.01% 5729
2015
Q3 		$50K Hold
5
– – ﹤0.01% 5730
2015
Q2 		$67K Buy
5
+1
+25% +$13.9K ﹤0.01% 5757
2015
Q1 		$56K Sell
4
-13
-76% -$156K ﹤0.01% 5753
2014
Q4 		$140K Buy
17
+7
+70% +$60.8K ﹤0.01% 5403
2014
Q3 		$120K Buy
10
+8
+400% +$87.5K ﹤0.01% 5389
2014
Q2 		$32K Hold
2
– – ﹤0.01% 5902
2014
Q1 		$38K Buy
+2
New +$37.5K ﹤0.01% 5804

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's GLMD Position: Q2 2026 in Review

Morgan Stanley reduced its Galmed Pharmaceuticals (GLMD) stake by 65% in Q2 2026, selling an estimated $65 and leaving 7 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #8228.

Morgan Stanley first reported a position in GLMD in Q1 2014 and has held it in 50 quarters since. The position peaked at $2.69M in Q2 2018. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • Morgan Stanley held 7 shares of Galmed Pharmaceuticals worth $31 as of Q2 2026.
  • Morgan Stanley sold 13 Galmed Pharmaceuticals shares in Q2 2026, an estimated $65.
  • Galmed Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8228 holding.
  • Morgan Stanley first reported a position in Galmed Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
  • Morgan Stanley's Galmed Pharmaceuticals position peaked at $2.69M in Q2 2018.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.